Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 22, 2024

Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Author(s)Robert O'Brien, RPh, Diana I. Brixner, PhD, RPh, Ashley Peterson, MHA

Medical experts identify key stakeholders within health plans who collaborate in the decision-making process for coverage, access, and benefit design related to prescription digital therapeutics.

Episodes in this series

Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"

EP. 1 Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"

EP. 2 Payer Needs and Strategies for Evaluating and Covering PDTs

A panel of 4 experts on PDTs

EP. 3 Payers Review Process and Effective Strategies for PDT Coverage

A panel of 4 experts on PDTs

EP. 4 Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

Video 5 - "Dawn of the Age of Adopting PDTs"

EP. 5 Dawn of the Age of Adopting PDTs

Video 6 -"Identifying the Most Impactful Disease Areas and Patient Populations for PDTs"

EP. 6 Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

4 KOLs discuss PDTs

EP. 7 Evolving Commercialization and Distribution Models for PDTs

4 KOLs discuss PDTs

EP. 8 Promoting Appropriate PDT Prescribing Through Provider Education and Support

A panel of 4 experts on PDTs

EP. 9 Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

A panel of 4 experts on PDTs

EP. 10 Optimizing Benefit Design and Implementation for Improved PDT Access

A panel of 4 experts on PDTs

EP. 11 PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Pills | Image Credit: bukhta79 - stock.adobe.com

Drug Development-to-Reimbursement Timelines Show Little Progress Over a Decade

ByBrooke McCormick

July 27th 2026

Asian elderly patient speaks with doctor | Image credit: M+Isolation+Photo - stock.adobe.com

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

July 27th 2026

Anti-VEGF Has Hit Its DME Ceiling: John Kitchens, MD

ByLaura Joszt, MA,John Kitchens, MD

July 27th 2026

Experts featured in this series.

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: July 27th 2026 | Updated: July 16th 2026

Experts featured in this series.

Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course

ByKavita Nair, PhD,Anton Porsteinsson , MD,Alireza Atri, MD, PhD

Published: July 27th 2026 | Updated: July 16th 2026

Trending on AJMC

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis

Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course

Small Workflow Changes Close Big Gaps in CKM Screening

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup